ATNX - Athenex says oral paclitaxel associated with survival benefit study shows

Athenex ([[ATNX]] -4.2%) has announced presentation of updated Phase 3 progression free ((PFS)) and overall survival ((OS)) data, demonstrating clinical benefits in efficacy and tolerability of oral paclitaxel vs. IV paclitaxel ((IVP)) in patients with metastatic breast cancer. Data were presented at the San Antonio Breast Cancer Symposium.In the intent-to-treat population, oral paclitaxel demonstrated a median PFS of 8.4 months vs. 7.4 months, with median OS of 22.7 months vs. 16.5 months.Safety analyses of as long as 112 weeks continue to demonstrate the reduction in incidence and severity of neuropathy favoring oral paclitaxel versus IVP: all grades of neuropathy were 22% vs. 64%, and severe neuropathy was 2% vs. 15%Oral paclitaxel has been granted Priority Review by the FDA for the treatment of metastatic breast cancer with action date of February 28, 2021.

For further details see:

Athenex says oral paclitaxel associated with survival benefit, study shows